Drug Profile
Elafibranor - Genfit
Alternative Names: GFT-505; IPN-60190Latest Information Update: 30 Apr 2024
Price :
$50
*
At a glance
- Originator Genfit
- Developer Genfit; Ipsen
- Class Anti-inflammatories; Antifibrotics; Antihyperglycaemics; Antihyperlipidaemics; Hepatoprotectants; Organic sulfur compounds; Phenyl ethers; Propionic acids; Small molecules
- Mechanism of Action Antioxidants; Peroxisome proliferator-activated receptor alpha agonists; Peroxisome proliferator-activated receptor delta agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Primary biliary cirrhosis
- Phase II Primary sclerosing cholangitis
- Discontinued Hepatic fibrosis; Lipid metabolism disorders; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Type 2 diabetes mellitus
Most Recent Events
- 25 Apr 2024 Ipsen plans the phase III ELSPIRE trial for Primary biliary cirrhosis (Treatment-experienced) (PO, Tablet) in July 2024 (NCT06383403) (EudraCT2024-510695-20-00
- 08 Feb 2024 Ipsen anticipates regulatory approval of elafibranor in Primary biliary cirrhosis (Treatment-experienced) in the EU, in the second half of 2024
- 08 Feb 2024 Ipsen anticipates regulatory approval of elafibranor in Primary biliary cirrhosis (Treatment-experienced) in the US, in the first half of 2024